Related Experiment Video
Updated: Oct 13, 2025
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis
Jennifer Curran1, Jennifer Lo2, Valerie Leung3
1Antimicrobial Stewardship Program, Sinai Health/University Health Network, Toronto, ONT, Canada.
Background:
There is growing evidence supporting the efficacy of shorter courses of antibiotic therapy for common infections. However, the risks of prolonged antibiotic duration are underappreciated.
Objectives:
To estimate the incremental daily risk of antibiotic-associated harms.
Methods:
We searched three major databases to retrieve systematic reviews from 2000 to 30 July 2020 in any language.
Eligibility:
Systematic reviews were required to evaluate shorter versus longer antibiotic therapy with fixed durations between 3 and 14 days. Randomized controlled trials included for meta-analysis were identified from the systematic reviews.
Participants:
Adult and paediatric patients from any setting.
Interventions:
Primary outcomes were the proportion of patients experiencing adverse drug events, superinfections and antimicrobial resistance.
Risk Of Bias Assessment:
Each randomized controlled trial was evaluated for quality by extracting the assessment reported by each systematic review.
Data Synthesis:
The daily odds ratio (OR) of antibiotic harm was estimated and pooled using random effects meta-analysis.
Results:
Thirty-five systematic reviews encompassing 71 eligible randomized controlled trials were included. Studies most commonly evaluated duration of therapy for respiratory tract (n = 36, 51%) and urinary tract (n = 29, 41%) infections. Overall, 23 174 patients were evaluated for antibiotic-associated harms. Adverse events (n = 20 345), superinfections (n = 5776) and antimicrobial resistance (n = 2330) were identified in 19.9% (n = 4039), 4.8% (n = 280) and 10.6% (n = 246) of patients, respectively. Each day of antibiotic therapy was associated with 4% increased odds of experiencing an adverse event (OR 1.04, 95% CI 1.02-1.07). Daily odds of severe adverse effects also increased (OR 1.09, 95% CI 1.00-1.19). The daily incremental odds of superinfection and antimicrobial resistance were OR 0.98 (0.92-1.06) and OR 1.03 (0.98-1.07), respectively.
Conclusion:
Each additional day of antibiotic therapy is associated with measurable antibiotic harm, particularly adverse events. These data may provide additional context for clinicians when weighing benefits versus risks of prolonged antibiotic therapy.
More Related Videos
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
08:33Quantitative Polymerase Chain Reaction-based Analyses of Murine Intestinal Microbiota After Oral Antibiotic Treatment
Published on: November 17, 2018
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
01:24Dosage Regimen: Individualization
01:19Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...